FDA Advisory Committee Recommends Approval of Drug to Treat Interstitial Lung Disease Caused by Systemic Sclerosis

According to a story from Healio, the US Food and Drug Administration's (FDA) Arthritis Advisory Committee recently voted 10-7 in favor of recommending the drug nintedanib as a treatment for…

Continue Reading FDA Advisory Committee Recommends Approval of Drug to Treat Interstitial Lung Disease Caused by Systemic Sclerosis
Hereditary Angioedema Drug Shows Safety and Efficacy in Pediatric Patients, Study Shows
cherylholt / Pixabay

Hereditary Angioedema Drug Shows Safety and Efficacy in Pediatric Patients, Study Shows

According to a story from Angioedema News, a recent clinical trial has demonstrated that the drug conestat alfa (marketed as Ruconest) was able to successfully treat 96 percent of acute…

Continue Reading Hereditary Angioedema Drug Shows Safety and Efficacy in Pediatric Patients, Study Shows

Study Findings Result in New Diagnostic Recommendations for Hereditary Angioedema in the ER

According to a story from Angioedema News, a team of researchers has used data from a recent study to provide up to date recommendations for diagnosing hereditary angioedema in the…

Continue Reading Study Findings Result in New Diagnostic Recommendations for Hereditary Angioedema in the ER
Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters
https://pixabay.com/en/sunset-sun-sisters-girl-shadow-929179/

Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters

An article from Comic Sands recently covered the story of a UK mother, Alison Beesley, who is now committed to taking care of her daughters Eliza and Eleanor full time. Eliza is nine years old and…

Continue Reading Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters

DNA Sequencing Took Years, Now it Takes Hours; As a Result, Researchers Have Discovered The Cause of Four Rare Diseases

Researchers at the University of Tokyo have discovered that one segment of DNA is responsible for four rare diseases. As reported in Science Daily, the university team also believes that…

Continue Reading DNA Sequencing Took Years, Now it Takes Hours; As a Result, Researchers Have Discovered The Cause of Four Rare Diseases

Experimental Treatment for Acute Myeloid Leukemia Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company Mustang Bio, Inc. has recently announced that the US Food and Drug Administration (FDA) has recently awarded the company Orphan Drug…

Continue Reading Experimental Treatment for Acute Myeloid Leukemia Earns Orphan Drug Designation
New Biosimilar to Rituxan Earns FDA Approval
source: pixabay.com

New Biosimilar to Rituxan Earns FDA Approval

According to a story from drugs.com, the pharmaceutical company Pfizer, Inc. recently issued an announcement detailing the approval of its drug Ruxience (rituximab-pvvr), a biosimilar to the widely used monoclonal…

Continue Reading New Biosimilar to Rituxan Earns FDA Approval
Apellis Pharmaceuticals Launches Program Investigating Potential of APL-9 for Preventing AAV Resistance in Gene Therapy
luvqs / Pixabay

Apellis Pharmaceuticals Launches Program Investigating Potential of APL-9 for Preventing AAV Resistance in Gene Therapy

According to a press release from the Kentucky-based Apellis Pharmaceuticals, the Company has initiated a program to investigate the use of APL-9, an investigational drug, in gene therapies that involve…

Continue Reading Apellis Pharmaceuticals Launches Program Investigating Potential of APL-9 for Preventing AAV Resistance in Gene Therapy
India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
klbz / Pixabay

India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases

According to a story from health.economictimes.indiatimes.com, the country of India is currently beginning to take more steps in order to address the dire unmet medical need of its rare disease…

Continue Reading India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
European Medicines Agency Grants Experimental Cystic Fibrosis Drug Orphan Drug Designation
source: pixabay.com

European Medicines Agency Grants Experimental Cystic Fibrosis Drug Orphan Drug Designation

According to a press release from Aridis Pharmaceuticals, the Company has received Orphan Drug designation from the European Medicines Agency for its experimental cystic fibrosis-related lung infection treatment AR-501. The…

Continue Reading European Medicines Agency Grants Experimental Cystic Fibrosis Drug Orphan Drug Designation
Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
source: pixabay.com

Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders

According to a press release from Takeda Pharmaceutical Company published by For Press Release, the Company has launched a collection of enzyme replacement therapies for use in the treatment of…

Continue Reading Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
First-of-its-Kind Study of Charcot-Marie-Tooth Disease Type 4J to Begin at UT Southwestern Med Center
Source: Pixabay

First-of-its-Kind Study of Charcot-Marie-Tooth Disease Type 4J to Begin at UT Southwestern Med Center

According to a publication from Charcot-Marie-Tooth News, the first patient has been enrolled in the first ever natural history study of type 4J Charcot-Marie-Tooth disease. Study collaborators — biotechnology company…

Continue Reading First-of-its-Kind Study of Charcot-Marie-Tooth Disease Type 4J to Begin at UT Southwestern Med Center
First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug
source: pixabay.com

First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug

According to a press release from the San Francisco-based FibroGen, Inc., the first patient has been dosed in the Company's phase 3 clinical study of the experimental drug pamrevlumab for…

Continue Reading First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug
Boston Children’s Hospital Studying Gene Therapy’s Potential for Treating CPVT Arrhythmia
source: pixabay.com

Boston Children’s Hospital Studying Gene Therapy’s Potential for Treating CPVT Arrhythmia

According to a publication from Fierce Biotech, researchers from Boston Children's Hospital have created a new gene therapy technique they believe could provide benefits to patients with inherited forms of…

Continue Reading Boston Children’s Hospital Studying Gene Therapy’s Potential for Treating CPVT Arrhythmia